I
Inflammatix
Biotech & Life Sciences · Sunnyvale, United States · Founded 2016
Developing novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system MoreLess
Inflammatix is a pioneering startup in the healthcare diagnostics sector, focusing on developing rapid point-of-care tests that read the immune system. The company aims to revolutionize how infections are diagnosed by leveraging a novel approach that examines the body's immune response rather than just looking for pathogens directly. This method allows for the accurate identification of bacterial and viral infections, as well as the severity of these infections, which is crucial for conditions like sepsis.
The primary clients for Inflammatix are healthcare providers, including hospitals, clinics, and urgent care centers. These institutions benefit from the company's technology by being able to make quicker and more accurate decisions regarding antibiotic prescriptions and patient admissions. This is particularly important in the context of acute infections, where timely and precise diagnosis can significantly impact patient outcomes.
Inflammatix operates in the medical diagnostics market, a rapidly growing sector driven by the increasing need for quick and reliable diagnostic solutions. The company's business model is centered around the development and commercialization of its diagnostic tests. Although their tests are not yet FDA-approved or CE-marked, they have been validated in numerous independent studies involving thousands of patients and published in leading medical journals.
Revenue generation for Inflammatix primarily comes from the sale of its diagnostic tests and related services. As the company continues to advance its technology and secure regulatory approvals, it is poised to capture a significant share of the diagnostics market, particularly in the areas of infectious diseases and sepsis.
In summary, Inflammatix is at the forefront of medical diagnostics innovation, offering rapid and accurate immune system-based tests to healthcare providers. The company is well-positioned to address major clinical and public health challenges, making it a valuable player in the healthcare industry.
Keywords: diagnostics, immune system, infections, sepsis, healthcare, rapid tests, bacterial, viral, point-of-care, innovation.
Company overview
Inflammatix company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Sunnyvale, United States
- Employees
- 76
- Open positions
- None listed
- Dealroom signal
- 66.6
Valuation & funding
Inflammatix funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Sep 2024 | $57M | $228M | Vesalius Biocapital Partners · Northpond Ventures · Khosla Ventures · OSF | ↗ |
| LATE VCOther financing | Jan 2023 | $0 | — | Iberis Capital | — |
| LATE VCOther financing | Nov 2021 | $12M | $48M | US Department of Health and Human Services | ↗ |
| GRANTOther financing | Nov 2021 | $1.7M | — | National Institutes of Health | ↗ |
| SERIES DOther financing | Mar 2021 | $102M | $408M | Think.Health · Northpond Ventures · D1 Capital Partners · Khosla Ventures | — |
| GRANTOther financing | Sep 2020 | DARPA | — | ||
| SERIES COther financing | Jan 2020 | Grey Sky Venture Partners · Northpond Ventures · Khosla Ventures · Think.Health | — | ||
| SERIES BOther financing | Oct 2018 | Northpond Ventures · Think.Health | — | ||
| SERIES AOther financing | Mar 2017 | Khosla Ventures | — | ||
| GRANTOther financing | Jan 2017 | DARPA | — |
Growth signals
Inflammatix website traffic
Latest recorded traffic for Inflammatix is 2.4K monthly website visits, down 42.9% over the last three months. Inflammatix's team grew 0% over the past year.
Hiring
Open positions at Inflammatix
Current openings linked to this company in Dealroom.
Comparisons
Inflammatix compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Inflammatix's talent
Source: Dealroom Talent Intelligence.
Investors
13 investors on Inflammatix's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.



Global footprint
Where Inflammatix has talent and traffic
team presence
In the news
Latest news about Inflammatix
Recent press, funding announcements, and product moves mentioning Inflammatix — open to read from the original sources.
Market sentiment
What the market is saying about Inflammatix
An AI-synthesized read of the highest-engagement posts about Inflammatix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inflammatix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.
















